Developments in identifying and managing mucormycosis in hematologic cancer patients.
Livio PaganoGiulia DragonettiElena De CarolisGiuseppe VeltriMaria Ilaria Del PrincipeAlessandro BuscaPublished in: Expert review of hematology (2020)
The epidemiology of mucormycosis in HMs is changing in the last years. The availability of drugs more effective than in the past against this infection has reduced the mortality; however, a timely diagnosis remains a relevant problem potentially influencing the outcome of hematologic patients with IM.